In Brief This Week: 454 Life Sciences; BioReference Laboratories; Sidmap; IDBS; GeneNews; and More

Apr 10, 2009

NEW YORK (GenomeWeb News) – Roche said this week that a paper published in the most recent issue of the Journal of Infectious Disease demonstrated that ultra-deep sequencing with 454 Life Sciences' sequencing system was able to identify low-frequency hepatitis B virus drug-resistant mutations in infected samples, including mutations that were undetected using standard direct PCR sequencing methods.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Making a Mark

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Optimistic, Though Cautious

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

And Maybe a Fee

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

Nature Highlights Study Finding Differences in Infant Gut Microbiome by Delivery Mode, More

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Menu